148 related articles for article (PubMed ID: 9520982)
1. Liver-specific MR imaging contrast agents.
Hahn PF; Saini S
Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
[TBL] [Abstract][Full Text] [Related]
2. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
De Gaspari A; De Cobelli F; Del Maschio A
Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of liver contrast agents: impact for clinical use.
Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
[TBL] [Abstract][Full Text] [Related]
4. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings.
Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR
Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426
[TBL] [Abstract][Full Text] [Related]
5. Contrast-enhanced MR imaging of the liver.
Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
[TBL] [Abstract][Full Text] [Related]
6. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
Tanimoto A; Kuribayashi S
Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
[TBL] [Abstract][Full Text] [Related]
8. [Organ specific MRI contrast media in general practice].
Schima W
Wien Med Wochenschr Suppl; 2002; (113):8-11. PubMed ID: 12621828
[TBL] [Abstract][Full Text] [Related]
9. Imaging liver metastases: review and update.
Kanematsu M; Kondo H; Goshima S; Kato H; Tsuge U; Hirose Y; Kim MJ; Moriyama N
Eur J Radiol; 2006 May; 58(2):217-28. PubMed ID: 16406434
[TBL] [Abstract][Full Text] [Related]
10. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
Petersein J; Saini S; Weissleder R
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of fatty liver with MR imaging.
Kreft BP; Tanimoto A; Baba Y; Zhao L; Chen J; Middleton MS; Compton CC; Finn JP; Stark DD
J Magn Reson Imaging; 1992; 2(4):463-71. PubMed ID: 1633400
[TBL] [Abstract][Full Text] [Related]
13. Liver-specific contrast agents for MRI.
Stark DD; Elizondo G; Fretz CJ
Invest Radiol; 1990 Sep; 25 Suppl 1():S58. PubMed ID: 2126535
[No Abstract] [Full Text] [Related]
14. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
[TBL] [Abstract][Full Text] [Related]
15. [Current status of the clinical development of MR contrast media].
Laniado M; Kopp AF
Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947
[TBL] [Abstract][Full Text] [Related]
16. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging.
Kim SK; Kim SH; Lee WJ; Kim H; Seo JW; Choi D; Lim HK; Lee SJ; Lim JH
AJR Am J Roentgenol; 2002 Sep; 179(3):741-50. PubMed ID: 12185056
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of gadoxetate disodium, manganese dipyridoxal diphosphate, and superparamagnetic iron oxide for enhancement of the liver in dogs.
Khangure MS; Hua J
Acad Radiol; 1996 Aug; 3 Suppl 2():S458-60. PubMed ID: 8796629
[No Abstract] [Full Text] [Related]
18. Safety of approved MR contrast media for intravenous injection.
Runge VM
J Magn Reson Imaging; 2000 Aug; 12(2):205-13. PubMed ID: 10931582
[TBL] [Abstract][Full Text] [Related]
19. Combined use of MR contrast agents for evaluating liver disease.
Ward J; Robinson PJ
Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
[TBL] [Abstract][Full Text] [Related]
20. Real enhancement or merely increased contrast?
Chen JH
AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
[No Abstract] [Full Text] [Related]
[Next] [New Search]